Tags: Cancer | US | MED | FDA | Breast | Cancer | Drug

US Approves First Drug for Inherited Breast Cancer

Image: US Approves First Drug for Inherited Breast Cancer
(Copyright DPC)

Friday, 12 Jan 2018 03:48 PM

U.S. regulators have approved the first drug aimed at women with advanced breast cancers caused by an inherited flawed gene.

The Food and Drug Administration on Friday approved AstraZeneca PLC's Lynparza (lihn-PAHR'zah) for patients with inherited BRCA gene mutations who have undergone chemotherapy.

It's the first in a fairly new class of medicines for ovarian cancer called PARP inhibitors to also win approval for treating breast cancer.

PARP inhibitors prevent cancer cells from fixing problems in their DNA. Blocking that can result in those cells dying or tumor growth slowing or even stopping.

AstraZeneca says Lynparza will cost $13,886 per month without insurance.

Possible side effects are less severe than for chemo, but can include serious ones such as blood and bone marrow cancers.

© Copyright 2018 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

   
1Like our page
2Share
Health-News
The FDA has approved the first drug aimed at women with advanced breast cancers caused by an inherited flawed gene.
US, MED, FDA, Breast, Cancer, Drug
124
2018-48-12
Friday, 12 Jan 2018 03:48 PM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved